| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
-Secreting T Cells After DNA-Based Immunization1
*
Unité de Recombinaison et Expression Génétique, Institut National de la Santé et de la Recherche Médicale, U163, Institut Pasteur, Paris, France; and
Centre de Recherche, Institut National de la Santé et de la Recherche Médicale, U347, Le Kremlin-Bicètre, France
The immunotherapeutic effect of DNA-mediated immunization against
chronic hepatitis B virus (HBV) infection has been evaluated in
transgenic mice expressing the sequences that code for the envelope
proteins of HBV in the liver. In this model of HBV chronic
carriers, a single i.m. injection of plasmid DNA encoding HBV envelope
proteins is sufficient to generate specific immune responses leading to
the clearance of the transgene expression product and the control of
HBV mRNA. The relative contributions of the T cell subpopulations
induced by DNA immunization were examined using adoptive transfer
experiments. It was shown that either CD8+ or
CD4+ T lymphocytes from immunocompetent DNA-immunized
animals were sufficient to control viral gene expression in the livers
of the recipient transgenic mice. This effect was mediated by a
cytokine-dependent mechanism common to both T cell subpopulations; this
mechanism did not require cell lysis, but did involve the production of
IFN-
by the activated T cells.
This article has been cited by other articles:
|
|
 |
|
  X. Li, X. Yang, Y. Jiang, and J. Liu A novel HBV DNA vaccine based on T cell epitopes and its potential therapeutic effect in HBV transgenic mice Int. Immunol., October 1, 2005; 17(10): 1293 - 1302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Loirat, M. Mancini-Bourgine, J.-P. Abastado, and M.-L. Michel HBsAg/HLA-A2 transgenic mice: a model for T cell tolerance to hepatitis B surface antigen in chronic hepatitis B virus infection Int. Immunol., October 1, 2003; 15(10): 1125 - 1136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Karayiannis Hepatitis B virus: old, new and future approaches to antiviral treatment J. Antimicrob. Chemother., April 1, 2003; 51(4): 761 - 785. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Marsac, D. Loirat, C. Petit, O. Schwartz, and M.-L. Michel Enhanced Presentation of Major Histocompatibility Complex Class I-Restricted Human Immunodeficiency Virus Type 1 (HIV-1) Gag-Specific Epitopes after DNA Immunization with Vectors Coding for Vesicular Stomatitis Virus Glycoprotein- Pseudotyped HIV-1 Gag Particles J. Virol., June 27, 2002; 76(15): 7544 - 7553. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Malanchere-Bres, P. J. Payette, M. Mancini, P. Tiollais, H. L. Davis, and M.-L. Michel CpG Oligodeoxynucleotides with Hepatitis B Surface Antigen (HBsAg) for Vaccination in HBsAg-Transgenic Mice J. Virol., July 15, 2001; 75(14): 6482 - 6491. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. Loirat, F. A. Lemonnier, and M.-L. Michel Multiepitopic HLA-A*0201-Restricted Immune Response Against Hepatitis B Surface Antigen After DNA-Based Immunization J. Immunol., October 15, 2000; 165(8): 4748 - 4755. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Schirmbeck, J. Wild, D. Stober, H. E. Blum, F. V. Chisari, M. Geissler, and J. Reimann Ongoing Murine T1 or T2 Immune Responses to the Hepatitis B Surface Antigen Are Excluded from the Liver that Expresses Transgene-Encoded Hepatitis B Surface Antigen J. Immunol., April 15, 2000; 164(8): 4235 - 4243. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
